Literature DB >> 16420477

Secretion of proteases in serglycin transfected Madin-Darby canine kidney cells.

Lillian Zernichow1, Knut T Dalen, Kristian Prydz, Jan-Olof Winberg, Svein O Kolset.   

Abstract

Madin-Darby canine kidney (MDCK) cells, which do not normally express the proteoglycan (PG) serglycin, were stably transfected with cDNA for human serglycin fused to a polyhistidine tag (His-tag). Clones with different levels of serglycin mRNA expression were generated. One clone with lower and one with higher serglycin mRNA expression were selected for this study. 35S-labelled serglycin in cell fractions and conditioned media was isolated using HisTrap affinity chromatography. Serglycin could also be detected in conditioned media using western blotting. To investigate the possible importance of serglycin linked to protease secretion, enzyme activities using chromogenic substrates and zymography were measured in cell fractions and serum-free conditioned media of the different clones. Cells were cultured in both the absence and presence of phorbol 12-myristate 13-acetate (PMA). In general, enzyme secretion was strongly enhanced by treatment with PMA. Our analyses revealed that the clone with the highest serglycin mRNA expression, level of HisTrap isolated 35S-labelled serglycin, and amount of serglycin core protein as detected by western blotting, also showed the highest secretion of proteases. Transfection of serglycin into MDCK cells clearly leads to changes in secretion levels of secreted endogenous proteases, and could provide further insight into the biosynthesis and secretion of serglycin and potential partner molecules.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16420477     DOI: 10.1111/j.1742-4658.2005.05085.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  7 in total

Review 1.  Cell-matrix interactions: focus on proteoglycan-proteinase interplay and pharmacological targeting in cancer.

Authors:  Achilleas D Theocharis; Chrisostomi Gialeli; Panagiotis Bouris; Efstathia Giannopoulou; Spyros S Skandalis; Alexios J Aletras; Renato V Iozzo; Nikos K Karamanos
Journal:  FEBS J       Date:  2014-11-06       Impact factor: 5.542

2.  Serglycin proteoglycan promotes apoptotic versus necrotic cell death in mast cells.

Authors:  Fabio R Melo; Mirjana Grujic; Jane Spirkoski; Gabriela Calounova; Gunnar Pejler
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

3.  Serglycin and secretion in human monocytes.

Authors:  Svein Olav Kolset; Lillian Zernichow
Journal:  Glycoconj J       Date:  2007-10-02       Impact factor: 2.916

4.  Serglycin is implicated in the promotion of aggressive phenotype of breast cancer cells.

Authors:  Angeliki Korpetinou; Spyros S Skandalis; Aristidis Moustakas; Kaisa E Happonen; Heidi Tveit; Kristian Prydz; Vassiliki T Labropoulou; Efstathia Giannopoulou; Haralambos P Kalofonos; Anna M Blom; Nikos K Karamanos; Achilleas D Theocharis
Journal:  PLoS One       Date:  2013-10-31       Impact factor: 3.240

Review 5.  Serglycin in human cancers.

Authors:  Xin-Jian Li; Chao-Nan Qian
Journal:  Chin J Cancer       Date:  2011-09

Review 6.  Serglycin: at the crossroad of inflammation and malignancy.

Authors:  Angeliki Korpetinou; Spyros S Skandalis; Vassiliki T Labropoulou; Gianna Smirlaki; Argyrios Noulas; Nikos K Karamanos; Achilleas D Theocharis
Journal:  Front Oncol       Date:  2014-01-13       Impact factor: 6.244

7.  Serglycin is part of the secretory repertoire of LPS-activated monocytes.

Authors:  Ingrid Benedicte M Kolseth; Trine Marita Reine; Tram Thu Vuong; Astri Jeanette Meen; Qiong Fan; Trond Geir Jenssen; Line Mariann Grønning-Wang; Svein Olav Kolset
Journal:  Immun Inflamm Dis       Date:  2015-02-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.